Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: A prospective, randomized, open-label study

Journal of Clinical Gastroenterology

Volumn 40, Issue 4, 2006, Pages 312-316

  Tursi, Antonio ^a,d   Brandimarte, Giovanni ^b   Giorgetti, Gian Marco ^c   Elisei, Walter ^b  

^a Lorenzo Bonomo Hospital   (Italy)

^b Cristo Re Hospital   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d NONE   (Italy)

Author keywords

Mesalazine; Probiotics; Recurrence; Symptomatic diverticular disease; Treatment

Indexed keywords

ENTEROLACTIS; MESALAZINE; PENTACOL; PROBIOTIC AGENT; PYRIDOXINE; RIBOFLAVIN; RIFAXIMIN; THIAMINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLON DIVERTICULOSIS; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LACTOBACILLUS CASEI; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUCUS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RECURRENT DISEASE; REMISSION;

EID: 33748160502     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000210092.77296.6d     Document Type: Article

References (26)

1. West AB, Losada M. The pathology of diverticulosis coli. J Clin Gastroenterol. 2004;38(Suppl. 1):S11-S16.
2. Tursi A. Acute diverticulitis of the colon - current medical therapeutic management. Expert Opin Pharmacother. 2004;5:145-149.
3. Tursi A, Brandimarte G, Daffinà R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Digest Liver Dis. 2002;34:510-515.
4. Brandimarte G, Tursi A. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit. 2004;10:170-173.
5. Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis. 2003;18:55-62.
6. Sanders ME. Probiotics. Food Technol. 1999;53:67-77.
7. Tursi A, Brandimarte G, Giorgetti GM, et al. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit. 2004;10:CR662-CR666.
8. Gionchetti P, Amadini C, Rizzello F, et al. Probiotics - role in inflammatory bowel disease. Digest Liver Dis. 2002;34(Suppl. 2):S58-S62.
9. Isolauri E. Probiotics for infectious diarrhoea. Gut. 2003;52:436-437.
10. Bazzocchi G, Gionchetti P, Almerigi PF, et al. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Digest Liver Dis. 2002;34(Suppl. 2):S48-S53.
11. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side-effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97:2744-2749.
12. Frič P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 2003;15:313-315.
13. Drago L, De Vecchi E, Valli M, et al. Colonizzazione intestinale di Lactobacillus casei subsp. Casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci & Terapia. 2002;XIX:72-XIX:76 (in Italian).
14. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108.
15. Cats A, Kuipers EJ, Bosschaert MAR, et al. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther. 2003;17:429-435.
16. Stollman NH, Raskin JB. Diverticular disease of the colon. J Clin Gastroenterol. 1999;29:241-252.
17. Tursi A. Preventive therapy for complicated diverticular disease of the colon: looking for a correct therapeutic approach. Gastroenterology. 2004;127:1865-1866.
18. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet. 1994;344:859-861.
19. Wood AJJ. Inflammatory bowel disease. N Engl J Med. 1996;334:841-848.
20. Gonçalves E, Almeida LM, Dinis TC. Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: a synergistic interaction? Free Rad Res. 1998;29:53-66.
21. Floch MH, Bina I. The natural history of diverticulitis: fact and theory. J Clin Gastroenterol. 2004;38(Suppl. 5):S2-S7.
22. Dugas B, Mercenier A, Lenoir-Wijnkoop I, et al. Immunity and probiotics. Immunol Today. 1999;20:387-390.
23. Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut. 1998;42:2-7.
24. Borruel N, Casellas F, Antolin M, et al. Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol. 2003;98:865-870.
25. Giaccari S, Tronci S, Falconieri M, et al. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur Rev Med Pharmacol Sci. 1993;XV:29-34.
26. Ferzoco LB, Raptopoulos V, Silen W. Acute diverticulitis. N Engl J Med. 1998;338:1521-1526.